A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia - Summary - MDSpire

A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia

  • By

  • Shannon Diggin

  • Laura Rueda-Delgado

  • Alison Buick

  • John F. Dyer

  • Azar Alexander-Sefre

  • Florentine Barbey

  • James B. Rowe

  • Kinan Muhammed

  • Brian T. Harel

  • Bryan J. Hansen

  • Elizabeth Tunbridge

  • Robert Lai

  • David J. Hawellek

  • Ann Marie Hake

  • Hugh Marston

  • Ashwini Oswal

  • Elizabeth Coulthard

  • Vivek Pattan

  • Victoria Evans

  • Stuart Gibson

  • Christopher Kipps

  • Rouba Kozak

  • Nick Mannering

  • Mark Moss

  • Viet Nguyen

  • Kenneth Ruddock

  • Leslie A. Shinobu

  • Sofia Toniolo

  • Brian Murphy

  • June 26, 2026

  • 0 min

Share

Objective:

To examine the feasibility of at-home measurement of neurocognitive function using the Cumulus Neuroscience NeuLogiq® platform in individuals with mild Alzheimer's Disease dementia and healthy controls over a 52-week period.

Approach:
  • Study Design: A 52-week longitudinal study involving individuals with mild AD dementia and healthy controls, focusing on usability and feasibility of the NeuLogiq® platform, including data collection methods and analysis.
Key Findings:
  • Participants with mild AD demonstrated a high adherence rate of 77% over the 52-week study.
  • Despite some technical challenges, participants reported strong engagement with the platform.
  • Lower confidence levels were noted among participants with dementia, with 31.6% expressing concerns about using the platform.
Interpretation:

The study indicates that individuals with mild Alzheimer's Disease can effectively use the NeuLogiq® platform for cognitive assessments at home.

Limitations:
  • Participants reported minor technical issues during initial setup, which may have affected their overall experience.
  • Confidence levels in using the platform were lower among dementia participants, potentially impacting their engagement.
Conclusion:

The findings support the practicality of using the NeuLogiq® platform for long-term assessments in patients with mild Alzheimer's Disease.

Original Source(s)

A real-world feasibility study: at home longitudinal use of the Cumulus NeuLogiq® platform for electrophysiological and neurocognitive measures in patients with mild Alzheimer's Disease dementia

  • by Shannon Diggin, Laura Rueda-Delgado, Alison Buick, John F. Dyer, Azar Alexander-Sefre, Florentine Barbey, James B. Rowe, Kinan Muhammed, Brian T. Harel, Bryan J. Hansen, Elizabeth Tunbridge, Robert Lai, David J. Hawellek, Ann Marie Hake, Hugh Marston, Ashwini Oswal, Elizabeth Coulthard, Vivek Pattan, Victoria Evans, Stuart Gibson, Christopher Kipps, Rouba Kozak, Nick Mannering, Mark Moss, Viet Nguyen, Kenneth Ruddock, Leslie A. Shinobu, Sofia Toniolo, Brian Murphy

  • June 26, 2026

Related Content

Pre-treatment structural brain biomarkers predict response to repetitive transcranial magnetic stimulation in subjective tinnitus

Long-term efficacy of neural circuit blockade for treating blepharospasm: a retrospective case series study

Exercise modulation of BDNF/TrkB signaling in Parkinson’s disease: an evidence-calibrated review of neuroprotective mechanisms, biomarker limitations, and translational gaps